Esfahani K - Search Results

1

Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.

Esfahani K, Aspler A, Menzies D, Schwartzman K. Esfahani K, et al. Int J Tuberc Lung Dis. 2011 Oct;15(10):1340-6. doi: 10.5588/ijtld.10.0575. Int J Tuberc Lung Dis. 2011. PMID: 22283892 Clinical Trial.

2

Moving towards personalized treatments of immune-related adverse events.

Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr, Calabrese L. Esfahani K, et al. Nat Rev Clin Oncol. 2020 Aug;17(8):504-515. doi: 10.1038/s41571-020-0352-8. Epub 2020 Apr 3. Nat Rev Clin Oncol. 2020. PMID: 32246128 Review.

3

A review of cancer immunotherapy: from the past, to the present, to the future.

Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, Miller WH Jr. Esfahani K, et al. Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97. doi: 10.3747/co.27.5223. Epub 2020 Apr 1. Curr Oncol. 2020. PMID: 32368178 Free PMC article. Review.

4

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation.

Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, Hudson M, Johnson NA, Baran D, Bhulaiga N, Takano T, Cailhier JF, Piccirillo CA, Miller WH. Esfahani K, et al. Nat Commun. 2019 Oct 17;10(1):4712. doi: 10.1038/s41467-019-12628-1. Nat Commun. 2019. PMID: 31624262 Free PMC article.

5

Programmed Cell Death Ligand 1-Induced Coma From Diffuse Cerebritis.

Desforges P, Esfahani K, Bouganim N. Desforges P, et al. Among authors: esfahani k. J Oncol Pract. 2018 Feb;14(2):134-135. doi: 10.1200/JOP.2017.024992. Epub 2017 Oct 10. J Oncol Pract. 2018. PMID: 29016224 No abstract available.

6

Acute liver failure because of chronic lymphocytic leukemia: case report and review of the literature.

Esfahani K, Gold P, Wakil S, Michel RP, Solymoss S. Esfahani K, et al. Curr Oncol. 2011 Jan;18(1):39-42. doi: 10.3747/co.v18i1.756. Curr Oncol. 2011. PMID: 21331280 Free PMC article.

7

Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy.

Almajed MM, Esfahani K, Pelmus M, Panasci L. Almajed MM, et al. Among authors: esfahani k. BMJ Case Rep. 2016 Jun 2;2016:bcr2016215525. doi: 10.1136/bcr-2016-215525. BMJ Case Rep. 2016. PMID: 27256996 Free PMC article.

8

Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.

Esfahani K, Miller WH Jr. Esfahani K, et al. N Engl J Med. 2017 May 18;376(20):1989-91. doi: 10.1056/NEJMc1703047. N Engl J Med. 2017. PMID: 28514612 No abstract available.

9

Erdheim-Chester Disease: The Importance of Information Integration.

Nikonova A, Esfahani K, Chausse G, Probst S, Petrogiannis-Haliotis T, Knecht H, Gyger G. Nikonova A, et al. Among authors: esfahani k. Case Rep Oncol. 2017 Jul 11;10(2):613-619. doi: 10.1159/000477658. eCollection 2017 May-Aug. Case Rep Oncol. 2017. PMID: 28868020 Free PMC article.

10

Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression.

Meti N, Petrogiannis-Haliotis T, Esfahani K. Meti N, et al. Among authors: esfahani k. J Oncol Pract. 2018 Aug;14(8):514-516. doi: 10.1200/JOP.18.00177. Epub 2018 Jul 13. J Oncol Pract. 2018. PMID: 30004823 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results